It doesn’t feel that way to consumers, though, and the QuintilesIMS report provides a pretty clear explanation of why. And some companies have sought to capitalize on high prices by jacking up prices dramatically, as occurred with Valeant Pharmaceuticals and Martin Shkreli. Looking at net prices, QuintilesIMS says, sales were $323 billion, up 4.8%. But in exceptional cases, patients have to pay way more. The end result is bitterly ironic: drug prices are coming under control, but many consumers aren’t benefiting.

Source: Forbes May 04, 2017 16:30 UTC